| Value | ₹2.10 Cr |
|---|
BSE filing, NSE: PPLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Piramal Pharma Ltd: key numbers
- Share price
- ₹230.05
- Market cap
- ₹30,628 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -146.7×Sector 46.1×
- Promoter holding
- 34.80%+0.00% QoQ
- FII holding
- 13.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.
Piramal Pharma Results Update
Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.
Piramal Pharma Q2 FY27 Results: Turns Profitable, Net Profit ₹5 Cr
Piramal Pharma Ltd reported revenue from operations of ₹2,617 Cr (+28.1% YoY) and net profit of ₹5 Cr for Q2 FY27.
- Key figure
- Net profit ₹5 Cr
Piramal Pharma Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.
Piramal Pharma Board Meeting Date
Piramal Pharma Limited has scheduled a board meeting on October 27, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.
Piramal Pharma Adverse Business Impact
Piramal Pharma announced that its sales and distribution arrangement with Bayer Pharmaceuticals will expire on December 31, 2026, and will not be renewed.
- From
- Bayer Pharmaceuticals Private Limited
Other employee stock options announcements
All →Motilal Oswal Financial Services Employee Stock Options
Motilal Oswal Financial Services granted 2,20,000 stock options to eligible employees under its ESOP Scheme X. No exercise price or monetary value is disclosed.
Borosil Employee Stock Options
Borosil granted 7,23,200 employee stock options at Rs 192.8 each under its 2020 scheme. Options vest in three tranches over three years.
- Execution
- Vesting over 3 years from grant date
Natco Pharma Employee Stock Options
Natco Pharma's insiders, including promoters and directors, were allotted equity shares. This allotment increases their total shareholding in the company.
- Value
- ₹144.2 Cr
Coforge Employee Stock Options
Coforge allotted 24,242 equity shares under its ESOP (2005) scheme on 29 October 2026. Paid-up capital rises to 44,30,62,864 equity shares.
Greenply Industries Employee Stock Options
Greenply Industries allotted 500 equity shares under its ESOP 2020 scheme on 29 October 2026. The allotment lifts paid-up capital to Rs.12,49,02,545.
Firstsource Solutions Employee Stock Options
Firstsource's Nomination and Remuneration Committee approved a grant of 587,750 stock options to eligible employees. The grant falls under its 2019 Employee Stock Option Plan.